anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a health-care medicine used for preventing and treating chronic pharyngitis, which comprises the following extracts of bulk drugs in parts by weight: 2.6 parts of honeysuckle, 3.4 parts of figwort, 2.5 parts of ophiopogon root, 1.7 parts of boat-fruited sterculia seed, 1.6 parts of gardenia, 1.7 parts of radix platycodi, 1.7 parts of cymose buckwheat rhizome, 1.7 parts of peppermint and 1 part of crude licorice. The health-care medicine adopts the food-medicine congeneric medicinal materials of the honeysuckle and the like as the main bulk drugs to extract the active components and adopts various nutrient substances with good paste forming property and low price and a little honey as auxiliary materials to prepare a honeyed paste. The health-care medicine not only has the functions of nourishing, nursing, preventing and treating chronic pharyngitis, throat gall and cough and the like but also has a favorable antibacterial action. The health-care medicine not only has unique mouth feel but also has low cost. The preparation method comprises the steps of decocting the bulk drugs, purifying liquor, concentrating the liquor and collecting the paste. By adopting a method combining a chemical method and a modern high-speed centrifugation technology to purify the liquor, the product purity and the production efficiency are obviously enhanced, and the sensory effect is improved.
Trigeminal Neuralgia (see INDICATIONS AND USAGE)

Initial: On the first day, 100 mg twice a day for tablets for a total daily dose of 200 mg. This daily dose may be increased by up to 200 mg/day using increments of 100 mg every 12 hours for tablets, only as needed to achieve freedom from pain. Do not exceed 1200 mg daily. 

Maintenance: Control of pain can be maintained in most patients with 400 to 800 mg daily. However, some patients may be maintained on as little as 200 mg daily, while others may require as much as 1200 mg daily. At least once every 3 months throughout the treatment period, attempts should be made to reduce the dose to the minimum effective level or even to discontinue the drug.
BACKGROUND: More than 80% of patients may experience acute pain after a surgical procedure, and this is often refractory to pharmacological intervention. The identification of new targets to treat postoperative pain is necessary. There is an association of polymorphisms in the Cav2.3 gene with postoperative pain and opioid consumption. Our study aimed to identify Cav2.3 as a potential target to treat postoperative pain and to reduce opioid-related side effects.
EXPERIMENTAL APPROACH: A plantar incision model was established in adult male and female C57BL/6 mice. Cav2.3 expression was detected by qPCR and suppressed by siRNA treatment. The antinociceptive efficacy and safety of a Cav2.3 blocker-alone or together with morphine-was also assessed after surgery.
KEY RESULTS: Paw incision in female and male mice caused acute nociception and increased Cav2.3 mRNA expression in the spinal cord but not in the incised tissue. Intrathecal treatment with siRNA against Cav2.3, but not with a scrambled siRNA, prevented the development of surgery-induced nociception in both male and female mice, with female mice experiencing long-lasting effects. High doses of i.t. SNX-482, a Cav2.3 channel blocker, or morphine injected alone, reversed postoperative nociception but also induced side effects. A combination of lower doses of morphine and SNX-482 mediated a long-lasting reversal of postsurgical pain in female and male mice.
CONCLUSION: Our results demonstrate that Cav2.3 has a pronociceptive role in the induction of postoperative pain, indicating that it is a potential target for the development of therapeutic approaches for the treatment of postoperative pain.
This study was planned to determine the effect of prenatal education given via podcast to nulliparous pregnant women who applied to the Non-Stress Test Polyclinic of the University of Health Sciences, Istanbul Bagcilar Training and Research Hospital, on maternal anxiety, fear and fetal attachment. The population of the research will consist of nulliparous pregnant women who applied to the Non-Stress Test polyclinic of the University of Health Sciences Istanbul Bağcılar Training and Research Hospital in 2024. The sample of the research will consist of 104 pregnant women who meet the sample selection criteria and participate in the study. Pregnant women who volunteer to participate in the research will be included in the study. The study will be carried out in two groups: the "intervention group", which receives prenatal education with podcasts, and the "control group", which receives routine care. Computer-assisted randomization will be used in the study, and the number of cases will be entered through the program with the URL address https://www. Random assignment was made to 52) and control (n:52) groups. Consent will be obtained from pregnant women using the "Informed Voluntary Consent Form" before the application. Pregnant women assigned to the intervention group will be given a 20-minute NST procedure while listening to a podcast on a Samsung Galaxy J7 Prime phone. Podcast duration is planned to be 5-6 minutes and 3 podcasts will be listened to. Pregnant women in the control group receive T.R. treatment within the scope of routine care. The Ministry of Health's booklet on pregnancy and birth process will be provided. "Personal Information Form", "State-Trait Anxiety Inventory", "Wijma Birth Expectation/Experience Scale Version A" and "Prenatal Attachment Inventory" will be applied to all pregnant women included in the study. Before the data collection forms are implemented, an "Informed Voluntary Consent Form" will be applied to the participants. State-Trait Anxiety Inventory", "Wijma Birth Expectation/Experience Scale Version A" and "Prenatal Attachment Inventory" will be applied to all groups before and after the intervention.
OBJECTIVES: The weight-adjusted waist circumference index (WWI), a novel obesity indicator, gives better accuracy in assessing both muscle and fat mass. Our goal was to evaluate the relationship between WWI and the occurrence of hyperuricemia/gout among middle-aged and older adults in America.
METHODS: We analyzed the National Health and Nutrition Examination Survey (NHANES) data from the 2007-2014 cycles. Logistic regression analyses, subgroup analyses, and restricted cubic splines (RCS) were performed to evaluate the association between WWI and hyperuricemia/gout prevalence.
RESULTS: A total of 5332 adults aged 50 years and above were included in this study. The prevalence of hyperuricemia and gout was 23.20% and 6.70% respectively. The fourth quartile of WWI was associated with a 56% higher risk for hyperuricemia, compared with the first quartile (OR = 1.56, 95% CI 1.07-2.27, P trend < 0.001). A similar association was found between continuous WWI increase and OR of hyperuricemia in the fully adjusted model (OR = 1.35, 95% CI = 1.13-1.61, P < 0.05). However, WWI was not significantly associated with the prevalence of gout. The RCS model suggested a significant linear relationship between WWI and the risk of hyperuricemia/gout. Stratification analysis showed that the positive associations of WWI with the risk of hyperuricemia were more pronounced in participants who were women, aged 50-59, smokers, no physical activity, non-diabetes, hypertension, and hyperlipidemia.
CONCLUSIONS: Our findings suggest a positive correlation between WWI and hyperuricemia among middle-aged and older adults in America. Employing WWI as a tool for hyperuricemia prevention may be meaningful. Key Points • Weight-adjusted waist circumference index is a new obesity evaluation index. • Weight-adjusted waist circumference index is associated with hyperuricemia not gout. • The association is more pronounced in participants who were women, aged 50-59, smokers, no physical activity, non-diabetes, hypertension, and hyperlipidemia.
Maternal glucose control is considered to be a major determinant of neonatal outcome in pregnancies complicated by diabetes. Studies have examined the link between neonatal mortality and morbidity using specific mean preprandial or postprandial plasma glucose levels, however, have not taken into account the daily wide excursions that occur in maternal glucose levels. Limited data are available on glucose variability (GV) in pregnancy and affect on maternal or neonatal outcomes. A recent study amongst diabetics showed that glucose variability between two data points, a morning fasting blood glucose and an afternoon blood glucose, increased the rate of adverse neonatal outcomes1. Glycosylated hemoglobin (A1c), which has been considered the "gold standard" for diabetes control since the Diabetes Control and Complication Trial (DCCT)2, lacks the specificity to predict pregnancy outcomes. Through review of data, we propose to examine other methods of evaluating daily maternal glucose variations to determine the correlation to maternal and neonatal outcomes.

The objective of this study is to determine the effect of glucose variability and/ or other elements on maternal and neonatal outcomes in the obese diabetic patient. We hypothesize that glucose variability will be a stronger indicator of neonatal outcome than A1c or any single given blood glucose value. Glucose variability, including the magnitude of hyperglycemia or the incidence of acute maternal hypo- or hyperglycemic events, will be explored. We hypothesise that obese pregnant women with higher magnitude of glucose fluctuations have more maternal and fetal co morbidities.
Patients undergo supervised 1-on-1 exercise sessions for 60 minutes on day 1.Treatment repeats every 3 weeks for up to 18 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive a home-based exercise prescription including instructions for keeping patients' heart rate within 50-80% maximum.
Participants receive venetoclax PO daily on days 1-28 and ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for up to 12 or 24 courses in the absence of disease progression or unacceptable toxicity. Participants with MRD negativity after 12 or 24 courses discontinue treatment, while participants with MRD positivity continue treatment with venetoclax in the absence of disease progression or unacceptable toxicity.
The patient receives the Hidrodilatation guided by ultrasonography under anesthetic blockage of the circumflex nerve and the supraescapular nerve. The hidrodilatation is achieved by insuflating the articulation with 2 cc of trigon depot + 10 cc 1% mepivacain + 11 cc saline serum.
This is a placebo that is used to counter Arm #2- the Ajovy® injections. Subjects in this arm will receive three saline injections at the start of month 2 that will mimic the Ajovy® injections. This will be conducted in a double-blind fashion, as both the clinician providing the injection, and the subject, will not know if the injection is actually Ajovy® or just saline.
Patients undergo standard of care radiation therapy daily 5 days a week and receive ONC206 PO up to six times per week. Cycles repeat every 28 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
BORUZU (1.3 mg/m2) is administered intravenously in combination with intravenous rituximab, cyclophosphamide, doxorubicin and oral prednisone (BR-CAP) for 6, three week treatment cycles as shown in Table 3. BORUZU is administered first followed by rituximab. BORUZU is administered twice weekly for two weeks (Days 1, 4, 8, and 11) followed by a ten day rest period on Days 12 to 21. For patients with a response first documented at Cycle 6, two additional BR-CAP cycles are recommended. At least 72 hours should elapse between consecutive doses of BORUZU.

Table 3: Dosage Regimen for Patients with Previously Untreated Mantle Cell Lymphoma
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a multisystem disorder with not only motor symptoms but also extra-motor features including cognitive impairment. The most common cognitive profile observed in patients with ALS includes deficits in executive function, language, and social cognition. However, longitudinal studies on cognitive changes over time in ALS are sparse. We aimed to investigate the presence and nature of cognitive impairment at the time of ALS diagnosis and its association with survival as well as explore longitudinal cognitive change.
METHOD: Patients (n = 216) were recruited at the Karolinska University Hospital in Stockholm, Sweden. Follow-up visits (n = 307 in total) were performed every 6 months. Cognitive impairment was assessed using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) and/or Montreal Cognitive Assessment (MoCA).
RESULTS: Cognitive impairment was observed in 38% of the patients at the time of ALS diagnosis, and the majority of these patients had deficits in executive function and/or language. Patients with cognitive impairment at the time of diagnosis had a more rapid decline in ALSFRS-R at 12- and 18-months follow-up, and a shorter survival. Cognitive function was stable during the first 2 years after diagnosis, and did not follow the trajectories of decline in motor functions.
CONCLUSION: Cognitive impairment in ALS was associated with a faster decline of motor functions, and shorter survival. However, cognitive function did not deteriorate over time. Cognitive assessment is essential for the patients and caregivers to understand the phenotypic expression of ALS.
The invention relates to medicine, biology, pharmacology, in particular to a method for immobilising a biologically active substance on a pharmacologically acceptable polymer carrier. The inventive method involves dissolving a biologically active substance in a polymer carrier aqueous solution, the concentration of which is greater than 0%, up to a saturated solution concentration and irradiating the reaction mixture by ionising radiation. In order to protect the biologically active substance from being destroyed by ionising radiation, the reaction mixture can be frozen at a temperature ranging from -20°C to -140°C prior to be irradiated. While being immobilised according to the inventive method, the biologically active substance is covalently linked to the polymer. The advantage of the inventive method consists in that it makes it possible to immobilise on the polymer carrier those water-soluble biologically active substances which are unstable, i.e., which are destroyed totally or in part when immobilised by the other methods and to increase the portion of the preserved biologically active substance when the biologically active substance is not totally destroyed during immobilisation. The conjugate as a biologically active substance carrier is characterised in that the biologically active substance is selected from a group comprising proinsulin, tyrosyl-2-alanyl-glyceryl-phenylalanyl-leucyl-arginine diacetate, alcalase, hyaluronidase, somatotropin and in that the carrier is in the form of a pharmacologically acceptable water-soluble polymer which is selected from a group comprising polyethylenoxide, polyvinylpyrrolidone, dextran, pluronic and acrilamide, wherein a biologically active substance molecule is covalently linked to at least one polymer molecule.
PURPOSE: Lactobacillus acidophilus HY 2177 and Lactobacillus casei HY 2743 having antimicrobial effects on Helicobacter pylori and their lactic acid bacterial preparations are provided. And fermented milk using the same is also provided. Therefore, they can be used in the prevention and treatment of Helicobacter pylori-related diseases. CONSTITUTION: The microorganisms, Lactobacillus acidophilus HY 2177 and Lactobacillus casei HY 2743, having antimicrobial effects on Helicobacter pylori are isolated by comparing the sizes of inhibition rings between Lactobacillus species containing L. acidophilus HY2105, HY 2177, HY 2109, HY 2185 and HY 2122, L. bulgaricus HY 2345 and HY 2350, L. casei HY 2726, HY 2772 and HY 2743, L. gaceri HY 2992, L. cryspatus HY 2830, L. brevis HY 2505, and L. plantarum HY 2207 and HY 2255 after incubation in brucella agar. The lactic acid bacterial preparations contain the combination of Lactobacillus acidophilus HY 2177 and Lactobacillus casei HY 2743 as active ingredients. The fermented milk contains the combination of Lactobacillus acidophilus HY 2177 and Lactobacillus casei HY 2743 as active ingredients.
This group will include 20 patients with liver cirrhosis as control group matching (stem cell group) in age, sex and child score. They will continue on the conventional therapy they already on and no stem cell transplantation will done for them.
FIELD: cattle breeding. SUBSTANCE: method involves parenteral administration of preparation obtained from the germinated grains in combination with sorbent intake, for example, zeolites. The germinated grains were used after preliminary removing high-molecular proteins and concentrating. This the combined and simultaneous parenteral administration of BAV-complex and oral administration of sorbents of the different nature shows the expressed enhancement of radionuclides elimination from organism of animals subjected for radioactive pollution. EFFECT: enhanced effectiveness of method. 1 tbl
Subjects with PG will be treated with 4 mg once daily of baricitinib for 24 weeks in addition to starting stable dose (at least 2 weeks) of prednisone at 30 mg daily. Prednisone will be tapered based on a pre-established algorithm assessed by investigator.
Brushing with specific brush and neutral soap, three times a day. After, immesion in saline solution during 20 minutes, once a day. This protocol was used during 7 days.
<P>PROBLEM TO BE SOLVED: To provide a method for safely, easily and efficiently producing a large quantity of a chitin/chitosan-containing polysaccharide compared to production methods using conventional microorganisms.  <P>SOLUTION: The method for safely, easily and efficiently producing a large quantity of a chitin/chitosan-containing polysaccharide is provided, comprising culturing and proliferating Geotrichum bacteria in a liquid medium. A fibrous product containing a large amount of the chitin/chitosan-containing polysaccharide is provided, being in the form of a multi-laminated structure. The fibrous product thus obtained can be used as a food material, a cosmetic material, a medical material, a cell-culturing sheet serving as a foothold in culturing totipotent stem cells or multipotent stem cells, or a drug carrier in DDS(drug delivery system). This fibrous polysaccharide-containing product, because of being in the form of a multi-laminated structure, can be put to a simple process to be formed into nonwoven fabrics or sheets.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Participants were given both Commercially available Biotrue ONEday lenses and Biotrue ONEday Contact Lenses with EPG03 Packaging Solution. Lens material is made from a hydrophilic copolymer of 2- hydroxyethyl methacrylate and N-vinylpyrrolidone and is 78% water by weight when immersed in saline solution. EPG03 Packaging Solution contains a phosphate buffered saline solution containing potassium chloride, poloxamine, poloxamer 181, glycerol (glycerin), erythritol, and polyquaternium-1.
Administer hydrocodone bitartrate and homatropine methylbromide oral solution by the oral route only. 

Always use an accurate milliliter measuring device when administering hydrocodone bitartrate and homatropine methylbromide oral solution to ensure that the dose is measured and administered accurately. A household teaspoon is not an accurate measuring device and could lead to overdosage [see Warnings and Precautions (5.5)]. For prescriptions where a measuring device is not provided, a pharmacist can provide an appropriate measuring device and can provide instructions for measuring the correct dose. Do not overfill. Rinse the measuring device with water after each use.

Advise patients not to increase the dose or dosing frequency of hydrocodone bitartrate and homatropine methylbromide oral solution because serious adverse events such as respiratory depression may occur with overdosage [see Warnings and Precautions (5.2), Overdosage (10)]. The dosage of hydrocodone bitartrate and homatropine methylbromide oral solution should not be increased if cough fails to respond; an unresponsive cough should be reevaluated for possible underlying pathology [see Dosage and Administration (2.3), Warnings and Precautions (5.4)].
The prevalence and accompanying morbidity and mortality of obesity and type 2 diabetes (T2D) is increasing on a global scale. Unfortunately the underlying (patho)physiological mechanisms are only partially understood. A key step in the development of negative health effects of metabolic disease might be via dietary fructose metabolism and its accompanying aberrant metabolite production, in which our gut microbiota plays a crucial role.

By bypassing the normal glucose metabolism pathway, fructose plays a role in the development of metabolic disease such as diabetes en fatty liver disease. The mechanism of this effect is unclear and possibly plays in the observation of ethnic specific metabolic risk factors. That is, subjects of different ethnicties (for instance South-Asian Surinamese (SAS)) have a higher risk and worse trajectory of metabolic diseases than Caucasians. Since gut microbiota is altered between these two ethnicities, we hypothesize that aberreant fructose catabolism in patients of SAS descent results in production of specific (gut microbiota derived) metabolites such as ethanol. In this study, fructose metabolism will thus be studied in patients of SAS and Caucasian Dutch descent. To this end the investigators will examine (13C stable isotope based) fructose fluxes before and after randomizing subjects into a four-week high- or low fructose diet. This study aims to elucidate the physiological and microbial catabolism of fructose and possible differences between these two ethnicities.
Fifty to 80% of women around menopause or already in postmenopause complain about symptoms such as hot flashes, night sweats, sleep disturbances, tiredness, and depression, which negatively impact their quality of life. The aim of this study was to evaluate the effects of a multiprobiotic strain on the quality of life and menopause-associated symptoms. The study is a de-centralized, prospective, randomized, placebo-controlled, double-blind study in which peri- and postmenopausal women will be recruited and randomly assigned (ratio 2:1) to receive either a probiotic blend or placebo formulation in capsules form for 12 weeks. We aim to recruit up to 300 women. On a monthly basis, quality of life will be evaluated by using the validated Spanish Quality of Life Cervantes questionnaire. In addition, other questionnaires will be administered to monitor menopause-related symptoms and health-related quality of life. This will be documented through a specifically designed, web-based platform. Main study variable is change in the global score in Cervantes quality of life questionnaire throughout study period.
Participants will follow a Well-Formulated Ketogenic Diet (WFKD) for 12 weeks. This diet will maximize the intake of non-processed beef, pork, and poultry (preferably organic/grass-fed), fish, heavy cream, low-lactose, high-fat cheeses, animal fats, oils (avocado, coconut, or other nut oils), non-starchy (above ground) vegetables and limited amounts of some fruits (berries). It will exclude legumes, grains, sugars, starchy (below ground) vegetables, most fruits, and polyunsaturated oils (soy, sunflower, peanut, cottonseed, canola, etc.). It will aim for an intake of 20 g of carbohydrates/day at start, with the goal to have no more than 50 grams/day to maintain ketosis.